Pretreatment inflammatory indices predict Bevacizumab response in recurrent Glioma

Aim: It remains unclear what the best therapeutic option for recurrent glioma patients after Stupp treatment is. Bevacizumab (BVZ) is commonly administered in progression, but it appears that only some patients benefit. It would be useful to find biomarkers that determine beforehand who these patien...

Descripción completa

Detalles Bibliográficos
Autores principales: Martínez-González, Alicia, Cabrera, Raquel, Lloret, Marta, Lara, Pedro C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: OAE Publishing Inc. 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8992487/
https://www.ncbi.nlm.nih.gov/pubmed/35582438
http://dx.doi.org/10.20517/cdr.2020.33

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8992487/
https://www.ncbi.nlm.nih.gov/pubmed/35582438
http://dx.doi.org/10.20517/cdr.2020.33

Ejemplares similares